Accuitive Medical Ventures is a venture capital firm with committed capital of $230 million. Our office is located in Atlanta, GA. We're a market driven firm looking for revolutionary medical device technology investment opportunities.
Our culture is about people, opportunities and experience. We have seen the venture world shift at startling speeds over the last few years, firms with a strong culture and a commitment to value creation —one that paints change as an opportunity to be embraced and not as an insurmountable threat—transform successfully without losing sight of their values.
We value teamwork, our commitment to an investment is a team investment, great wins come from great teamwork, and successful investment results are almost always based on collaborative debate and discussion among the partners.
Our investment approach mirror’s our culture and is more than just providing capital. We bring to bear our operational expertise, a focused group of hands-on entrepreneurial experience, we know what separates success from failure. While we assume that anything is possible we base our decisions on strong science, market knowledge, team dynamics and force vigorous debate among the partners before we commit capital.
Partner experience; we believe that our key advantage is the fact we have lived in the trenches, understand the series of challenges that must be solved to reach a successful exit and have the grit to persevere. We expect that our participation will require rolling up our sleeves, digging in with management and together changing the trajectory of the opportunity.
We make a commitment to long-term relationships with entrepreneurs, market analysts, and other venture capitalists building trust and respect such that our relationships will work with us on numerous opportunities.
Collaborative partnership with our portfolio companies and management. We participate in the strategy and goal setting of our portfolio Companies, Board meetings are opportunities to demonstrate our passion and commitment, not a vehicle to gain air miles.
Our team is focused on being significant investors in a manageable number of superior investments. We target excellent management teams with great ideas based on outstanding science with the potential for developing, delivering and sustaining differentiated value propositions and competitive advantages in creating strategic assets.
The Fund’s heritage is based on over 140 years combined experience of our partners in healthcare.
We look for medical device, diagnostic, drug/device and healthcare IT investments where we can use our engineering, regulatory, commercial, financial and operating experience to either help build a world class opportunity or enhance probability of commercial success of our portfolio Companies in delivering superior returns. We take an entrepreneurial approach to investing in opportunistic ideas where our experience suggests our influence can help drive a significant win.
We will not invest in invest in a company’s balance sheet and infrastructure or participate in funding during a pivotal clinical trial. We will avoid those later stages where competitive shakeouts and consolidations are inevitable and anticipated growth rates, in our opinion, cannot be sustained, we are not going to consider “tuck-ins” or product extensions.
We have always had high standards for performance, employed creative problem solving, demonstrated passion for success, debated risk/reward as a component of our decision making, and a get the job done philosophy.
Accuitive Medical Ventures has a strong relationship with The Innovation Factory (TIF), the successful medical technology serial operating team. TIF has started thirteen companies since 1999 and is based in Atlanta, GA. In conjunction with TIF, Accuitive Medical Ventures has the resources and experience to create long-term value for all medical technology stakeholders.
Accuitive has established relationships with some of the industry’s leading institutions to offer emerging companies and investors the opportunity to build unique new businesses and long-term shareholder value. Accuitive’s connections to some of the industry’s leading practitioners, thought leaders and venture capital firms enable us to add substantial value as investors and board members.
The Firm’s approach to working with management teams starts with a basic tenet that having a great, defensible business idea in a scalable market is only one component to attracting our investment commitment. A significant element is having a back-able management team that can execute the plan.
Our philosophy is simple, we don’t care about titles, we focus on skill sets. We want to know that the team can carry out the plan they have described; is there the experience, passion, drive and personal character to deliver when confronted with seemingly insurmountable obstacles.
Management teams that are attractive to the Firm include people who not only have the skills to succeed in their business but are also entrepreneurs who are more interested in making money than in running a business for life.
We believe in a well-articulated compensation plan, in many cases we take the lead in establishing the core of an incentive plan (MyoScience, Sebacia, AqueSys, Wave Tec).
A critical element of any compensation plan requires first an understanding of the organizations Vison and Values and what the enterprise value proposition is, this demonstrates managements passion.
If management can’t rally the team around a common value proposition, they can’t lead the Company to a spectacular exit.
The compensation plan is in place to motivate the portfolio company to focus on their vision and values and to ensure success of the entire organization in delivering their value proposition. The compensation program is designed to provide financial reward using a combination of base salary, target bonus and equity in the form of options all based on achievement of specific performance targets. We want to reward team members for achieving stretch annual goals and to closely align their accomplishments with the interests of the company’s shareholders.
We request to be part of the Compensation Committee of the portfolio company.
Passionate, successful teams with strong leadership we can invest in to move exciting technology forward.
creative individuals and groups who would benefit from the business and medical device experience that partnering with The Innovation Factory provides.
The device or technology must have the potential to serve a large addressable global market.
The technology should be novel with robust intellectual property protection.
The technology should create a new treatment modality or represent a substantial improvement.
The technology should have a business model that provides a sustainable advantage.
The technology must have definable regulatory, clinical, and reimbursement (if applicable) paths.
The technology must fit an area of strategic need for potential acquirers.
AMV is a business builder. We partner with entrepreneurs and assist them through the growth stages of their businesses towards an exit.
AcuFocus has developed and is marketing an innovative Intraocular Lens technology to treat presbyopia. AcuFocus was founded within The Innovation Factory.
Coinvestors include Versant Ventures, The Carlyle Group, SV Life Sciences, Sightline, Bausch & Lomb, Medtronic Inc., and Cowen Healthcare Royalty Partners.
AqueSys developed a novel implant to lower intraocular pressure in glaucoma patients. AqueSys was founded within The Innovation Factory.
Coinvestors included SV Life Sciences, The Carlyle Group, Longitude Venture Partners, and RHO Ventures.
Aquesys was acquired by Allergan, Inc.
AxoGen provides surgeons a novel solution to repair and regenerate peripheral nerves.
CardioFocus has developed and is marketing a catheter-based approach to treating atrial fibrillation.
Coinvestors include Oxford Biosciences, SV Life Sciences, H.I.G. Ventures, Aurora Funds, and KBL Healthcare Ventures.
Inogen has commercialized low-weight, portable oxygen concentrators to serve as full-time replacement devices for the home oxygen market.
Coinvestors included Versant Ventures, Novo Ventures, Arboretum Ventures, Avalon Ventures, and Magnetic Moments.
Intuity Medical is commercializing a novel fully integrated blood glucose monitor for the diabetes market.
Coinvestors include Versant Ventures, USVP, Venrock, IGC, PTV, KCK, Luther and Emergent Medical Partners.
LipoSonix focuses on providing a non-invasive alternative to liposuction surgery using High Intensity Focused Ultrasound (HIFU) technology. LipoSonix was founded within The Innovation Factory and was acquired by Medicis Pharmaceutical Corporation. LipoSonix currently operates within Valeant, Inc.
Coinvestors included Three Arch Partners, Versant Ventures, Delphi Ventures, The Carlyle Group, Essex Woodlands Health Ventures, Pinnacle Ventures, and SV Life Sciences.
MyoScience is developing novel technologies to replace opioids for osteopathic pain relief.
Coinvestors include De Novo Ventures, Nexus Medical, and Saratoga Ventures.
Neuronetics has developed and commercialized a Transcranial Magnetic Stimulation (TMS) system to treat depression. Neuronetics was founded within The Innovation Factory.
Coinvestors include New Leaf Partners, Three Arch Partners, InterWest Partners, ONSET Ventures, Quaker Bioventures, KBL Healthcare Ventures, Investor AB, Polaris Ventures, and Pfizer Ventures.
Nevro is a medical device company developing an implantable device for the treatment of chronic pain.
Coinvestors included Aberdare Ventures, Bay City Capital, Three Arch Partners, MPM Capital, Mayo Medical Ventures and Johnson & Johnson Development Corporation.
Respicardia is developing a central Sleep Apnea neurostimulation technology to treat and prevent Congestive Heart Failure.
Coinvestors include Versant Ventures, Three Arch Partners, Polaris Ventures, Affinity Capital, RK Ventures Group, and Abbott Ventures.
Sadra Medical developed minimally invasive alternatives to surgical aortic valve replacement.
Sadra Medical was acquired by Boston Scientific (NYSE: BSX).
Sebacia is developing novel technology to address a large unmet need in Acne Therapy. The company was founded and is currently operating within The Innovation Factory.
Coinvestors include Versant Ventures, Domain Associates, Salem Partners and The Partners Healthcare Innovation Fund.
Softscope developed a disposable accessory for use with existing colonoscopes that makes colonoscopy more comfortable for patients, easier and faster for physicians and potentially eliminate the need for I.V. sedation.
SoftScope was acquired by Fujinon.
Torax Medical has developed and commercialized a minimally invasive reflux management system for the treatment of GERD.
Coinvestors included Thomas, McNerney and Partners, Sanderling Ventures, Mayo Medical Ventures, and Kaiser Permanente.
Torax was acquired by Johnson and Johnson.
WaveTec Vision developed and commercialized a novel wavefront measurement technology that provides on-demand, intraoperative information to cataract and refractive surgeons.
Coinvestors included Versant Ventures, De Novo Ventures, Gund Investments, and Burrill & Company.
WaveTec was acquired by Alcon, a division of Novartis.
MARLBOROUGH, Mass., May 9, 2018 /PRNewswire/ -- CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), today announced a successful live case featuring its breakthrough HeartLight X3 System during the annual Prague Workshop on Catheter Ablation.
Building upon the advanced features of the current HeartLight Endoscopic Ablation System - direct tissue visualization, titratable laser energy, and compliant balloon technology - HeartLight X3 is designed to deliver rapid, continuous, 360-degree lesions, potentially making it the ultimate pulmonary vein isolation (PVI) tool for AF. The system offers a new "RAPID mode". This new mode of operation leverages a precise motor control system that enables uninterrupted, high-speed lesion creation.
The procedure, broadcast live during the workshop, demonstrated the breakthrough potential of the HeartLight X3 system. Successful PVI was achieved with a total energy delivery time of under 20 minutes. Performed by Petr Neužil, MD, PhD, Head of the Department of Cardiology at Na Homolce Hospital in Prague, Czech Republic and Vivek Y. Reddy, MD, Director of Cardiac Electrophysiology and Helmsley Trust Professor of Medicine at The Icahn School of Medicine at Mount Sinai, the case was part of the ongoing clinical evaluation of the HeartLight X3 System.
"The HeartLight X3 System is demonstrating an unprecedented combination of flexibility and speed," said Prof. Neužil "The HeartLight Excalibur Balloon™ enables wide areas of tissue contact outside of the pulmonary veins, allowing for the system's new RAPID mode to create never-seen-before circumferential, transmural lesion sets. RAPID mode allows for titratable, high-power energy delivery that enables fast ablations. The HeartLight X3 System truly holds the potential to be a breakthrough technology in the AF ablation space."
More than 33 million patients worldwide suffer from AF.1 AF, the most common type of cardiac rhythm disorder, prevents blood from being pumped efficiently, which can lead to stroke, weakness, breathlessness, fainting, and a significant reduction in quality of life. PVI with the HeartLight X3 System utilizes laser energy to create lines of scar tissue to block abnormal electrical pathways that cause AF.
"CardioFocus is dedicated to continuous advancement of its leading AF treatment platform, the HeartLight Endoscopic Ablation System," said Burke T. Barrett, Chief Operating Officer at CardioFocus. "Prof. Neužil and Prof. Reddy demonstrated the remarkable potential of the HeartLight X3 System during the Prague Workshop and I am thrilled with the progress we are making with the ongoing clinical evaluation. We look forward to continuing the study and subsequently establishing our plans for commercial introduction of the HeartLight X3 System."
The HeartLight X3 System is investigational and not available for sale.
The Excalibur Balloon leverages the proven universal balloon design of the company's FDA-approved HeartLight® Endoscopic Ablation System and introduces an advanced feature set that optimizes the speed and magnitude of target tissue contact during pulmonary vein isolation (PVI) procedures.
MARLBOROUGH, Mass., May 7, 2018 /PRNewswire/ -- CardioFocus, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the HeartLight Excalibur Balloon, a next-generation technology designed for the treatment of paroxysmal atrial fibrillation (PAF)*.
"We have seen encouraging results with the Excalibur Balloon. It obtains an impressive antral position and establishes even more tissue contact, which enables contiguous lesion sets," said Vivek Y. Reddy, MD, Director of Cardiac Electrophysiology and Helmsley Trust Professor of Medicine at The Icahn School of Medicine at Mount Sinai. "This is a clear advance in the field of balloon-based AF ablation, delivering on the promise of an ultra-compliant balloon."
In addition to its ultra-compliant design that enables adaptive vein conformance, the Excalibur Balloon also incorporates proprietary Dynamic Response™ technology. This feature allows the user to make real-time adjustments to balloon size, allowing for optimal tissue contact. These combined features are designed to maximize the engagement of the balloon with the pulmonary veins, while decreasing the time required to complete ablation procedures.
"The FDA approval of the Excalibur Balloon is a significant milestone for CardioFocus, as it is the first ultra-compliant balloon introduced into the US market for AF ablation," said Burke T. Barrett, Chief Operating Officer of CardioFocus. "The Excalibur Balloon capitalizes on the existing features of our HeartLight System, which offer an accurate, consistent, and controlled treatment option for PAF patients whose atrial arrhythmias are insufficiently controlled with medication*."
CardioFocus has successfully launched the Excalibur Balloon in Europe following CE Mark approval in September 2017. The technology is now offered at 20 European centers. The company expects to begin a full commercial launch of the Excalibur Balloon in the U.S. in the third quarter of 2018.
1 Go AS, et al. Prevalence of diagnosed atrial fibrillation in adults. JAMA. 2001;285:2370-2375.
2 Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114:119–25.
FREMONT, Calif., Jan. 8, 2018 /PRNewswire/ -- Intuity Medical, Inc., a privately-held company developing innovative technologies for diabetes management, announced today that it has closed $42.5M in the initial tranche of a $70M total round of funding which includes $40M in equity financing from Intuity's existing investors, including Accuitive Medical Ventures, Investor Growth Capital, KCK Group, affiliates of Luther King Capital Management, PTV Healthcare Capital, U.S. Venture Partners and Versant Ventures, plus $30M in debt financing from Hercules Capital.
Intuity's POGO® Automatic™ Blood Glucose Monitoring System, which has received clearance from the U.S. Food and Drug Administration (FDA), is the first blood glucose meter and multi-test cartridge to provide automatic testing with lancing, blood collection and analysis in one easy step without the need for separate strips and lancets. By combining all of the necessary blood glucose testing supplies into a self-contained 10-test cartridge, POGO provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose in the management of their diabetes.
"Our mission is focused on simplifying diabetes management for patients and their care circle," said Emory Anderson, President and CEO, Intuity Medical. "This funding will help strengthen our financial position to commercialize POGO and Patterns in the U.S., thanks to partners like our existing investors and Hercules Capital, who understand our business and support our vision."
Unlike other meters, POGO does not require a patient to use individual test strips or a separate lancing device, which eliminates carrying and disposing of multiple supplies. This means patients can quickly perform a glucose test while on the go or in public settings.
"We are pleased to partner with Intuity Medical at this important stage of the company's launch preparation for POGO and Patterns, and to provide growth capital to help the company address the potential market opportunity for POGO," said Scott Bluestein, Chief Investment Officer at Hercules Capital. "This investment in Intuity exemplifies our ability to create flexible and custom financing solutions for innovative Life Sciences companies, helping them achieve important milestones through multiple growth stages of development."
The number of adults with diabetes is a staggering 422 million worldwide, with the disease being the 7th leading cause of death in the U.S. According to the American Diabetes Association, nearly half of the 29 million U.S. patients are not achieving glycemic control in the management of their diabetes. The burdens associated with blood glucose testing are among the reasons for poor glycemic control; many patients cite lack of both simplicity and discretion as barriers to testing with their current meters.
Armentum Partners acted as financial advisor to Intuity Medical in conjunction with the debt financing.
MINNETONKA, Minn., Feb. 2, 2018 /PRNewswire/ -- Respicardia, Inc., a medical technology company developing innovative therapies that improve cardiovascular health, announced today that the first U.S. commercial case using the remedē® System to treat central sleep apnea was completed at The Ohio State University Wexner Medical Center in Columbus, Ohio by Ralph Augostini, MD, FACC, FHRS, Bob and Corrine Frick Chair in Cardiac Electrophysiology, Associate Professor of Medicine and co-director of the electrophysiology training program. The first case coincides with the naming of seasoned medical device executive, Peter Sommerness, as CEO of Respicardia and leader of the remedē System U.S. launch.
"The remedē System is a breakthrough technology that uniquely treats central sleep apnea while greatly improving a patient's quality of life," stated Dr. Augostini. "I am proud to be a part of the system's first U.S. commercial case that has the potential to become the standard of care for these patients."
Central Sleep Apnea (CSA) is a serious breathing disorder that disrupts the normal breathing pattern during sleep and negatively affects quality of life and overall cardiovascular health. CSA results from the brain's inability to send appropriate signals to the respiratory muscles to stimulate breathing. The remedē System is clinically proven to safely and effectively treat moderate to severe CSA in adult patients and improve quality of life.
"Central sleep apnea is very common in cardiac patients, especially patients with heart failure, and is associated with a significantly greater risk for morbidity and mortality," explained William Abraham, MD, Professor of Internal Medicine and Chief of the Division of Cardiovascular Medicine at The Ohio State University Wexner Medical Center. "Being able to treat CSA offers a new hope to improve the quality of life for my patients."
In addition to its first U.S. commercial implant, Respicardia announces today that it has appointed Peter Sommerness as CEO. Mr. Sommerness brings 20 years of commercial and operational experience from the electrophysiology and cardiac rhythm management markets. Most recently, Mr. Sommerness was a Partner at McKinsey and Company, where he was a leader in the global medical device practice, focusing on commercialization strategies, product launches, and operational improvement initiatives. Prior to this, he held the role of General Manager and Vice President of Cardiac Electrophysiology at Boston Scientific, where he was responsible for business unit strategy, portfolio and commercial execution.
"I'm excited to join Respicardia and its seasoned team at such a pivotal moment," stated Mr. Sommerness. "With the major milestone of our first U.S. commercial implant, I look forward to building on this momentum in the U.S. market and to bringing this groundbreaking technology to patients suffering from the harmful effects of central sleep apnea."
MINNETONKA, Minn., Dec. 18, 2017 /PRNewswire/ -- Respicardia, Inc., a private medical technology company, announced today that the company has closed a $58.5 million financing, led by ZOLL Medical Corporation, a leading manufacturer of medical devices and related software solutions. All of Respicardia's existing major investors helped to complete the financing round.
"We believe the remedē® System will soon become the treatment of choice for patients suffering from central sleep apnea and are pleased to receive significant funding from ZOLL in support of this important mission," stated Bonnie Labosky, President and CEO of Respicardia. "Proceeds from the financing will be used to fund our U.S. commercialization efforts and support ongoing development of the system."
"The remedē System is a breakthrough technology that uniquely treats the devastating effects CSA has on a person's quality of life and cardiovascular health," explained Jonathan A. Rennert, CEO of ZOLL. "This investment in Respicardia exemplifies ZOLL's commitment to advance novel therapies, especially those that address heart failure or one of its many co-morbidities such as central sleep apnea."
About the remedē System Pivotal Trial The remedē System Pivotal Trial, a prospective, multicenter, randomized controlled trial, evaluated the safety and effectiveness of transvenous phrenic nerve stimulation using the remedē System in patients with moderate to severe CSA. The primary effectiveness outcome was a comparison of the proportion of patients in the treatment versus control groups achieving a reduction in apnea-hypopnea index (AHI) of 50 percent or greater from baseline to 6 months. Clinical investigators at 31 sites in the United States and Europe implanted the remedē System in 151 patients and randomized them 1:1 to the treatment or control group. The trial met its primary endpoint for efficacy. In the modified intention-to-treat population, significantly more patients in the treatment group achieved 50 percent or greater reduction in AHI from baseline to 6 months than those in the control group with a clinically meaningful difference of 41% (p<0.0001). Additionally, the 12-month freedom from serious adverse events related to the implant procedure, remedē System or delivered therapy was 91 percent.
May 07, 2018 Sebacia Announces Favorable Ruling by U.S. Court of Appeals for the Federal Circuit Regarding Patent Interference Proceedings with Sienna Biopharmaceuticals, Inc.
The ruling relates to a patent interference proceeding between The General Hospital Corporation (GHC, the owner of certain patents licensed by Sebacia) and Sienna Biopharmaceuticals, Inc.
DULUTH, Ga., May 7, 2018 /PRNewswire/ -- Sebacia, Inc., a privately held dermatology and aesthetics company, today announced a precedential ruling from the U.S. Court of Appeals for the Federal Circuit. The ruling relates to a patent interference proceeding between The General Hospital Corporation (GHC, the owner of certain patents licensed by Sebacia) and Sienna Biopharmaceuticals, Inc. The Federal Circuit ruled in favor of GHC deciding that the Patent Trial and Appeal Board (PTAB) was arbitrary and capricious in terminating a patent interference proceeding initiated at GHC's suggestion concerning Sienna's Patent No. 8,812,941. The Federal Circuit remanded the interference proceeding for the PTAB to determine who between GHC and Sienna was the first to invent the subject matter covered by Claim 1 of the patent.
Anthony Lando, CEO of Sebacia, commented, "We are pleased with the outcome of this precedential decision by the Federal Circuit, and we look forward to further proceedings within the PTAB focused on determining first to invent."
The referenced case is General Hospital Corp. v. Sienna Biopharmaceuticals Inc., case number 17-1012, in the U.S. Court of Appeals for the Federal Circuit.
DULUTH, Ga., July 25, 2017 /PRNewswire/ -- Sebacia, Inc., a privately held, clinical and commercial stage dermatology and aesthetics company, today announced that the company has completed a $20 million Series D financing led by existing investors Versant Ventures, Domain Associates, Accuitive Medical Ventures and Partners Healthcare Innovation Fund. New investors accounted for approximately 60 percent of the round and include Salem Partners and other undisclosed investors. Additionally, Sebacia closed a $16 million debt facility with Hercules Capital.
"At this pivotal time, we are grateful for the continued support of our top-tier venture capital syndicate and energized by the addition of Salem Partners and other new investors," said Anthony V. Lando, Sebacia's Chief Executive Officer. "From intellectual property to extensive clinical experience and a defined clinical path to approval, we believe we have all the pieces to bring Sebacia's breakthrough treatment for acne to market in Europe and the United States."
John Dyett of Salem Partners said, "We have been very impressed by the Sebacia team and are excited to join such a distinguished group of institutional life sciences investors."
Sebacia is developing a proprietary microparticle treatment for moderate to severe acne. Sebacia's microparticles are delivered in a topical suspension specifically designed to work with hair removal or pigmented lesion treatment laser systems, which are already owned by the dermatologist. The Sebacia treatment is intended to be a simple, physician-guided, in-office procedure that could provide an alternative to existing therapies, such as oral antibiotics and isotretinoin. Sebacia has extensive clinical experience with nearly 2,000 treatments performed to date. The procedure is CE Marked in Europe and is being evaluated in clinical studies in the United States.
Feb 17, 2017 Ethicon Announces Agreement to Acquire Torax Medical, Inc.
This LINX® Reflux Management System is a small implant comprised of interlinked titanium beads with magnetic cores which augment the body's natural barrier function to prevent reflux. LINX is currently used by physicians in over 300 hospitals in the United States and Europe. This acquisition is consistent with Ethicon's strategy of advancing innovation and investing in areas of unmet medical needs such as esophageal health.
If your business or technology is ready to partner with AMV, please submit your business plan for review.
Tom has been a pioneer in health care for three decades and holds 30 U.S. patents for medical devices.
Mr. Weldon’s expertise is envisioning new market opportunities, driving businesses to become more successful and getting them to a liquidity event. He has cofounded more than a dozen companies including: Novoste, AcuFocus, AqueSys, LipoSonix, and Neuronetics, which in total have created more than $2 billion in shareholder value.
In addition, Tom has served on the board of numerous private companies, Universities and Foundations including Respicardia, Mednova and MyoScience. Today, he is the founder, chairman and CEO of Ponce De Leon Pharmaceuticals, which focuses on increasing human health span. He also serves as Chairman of The Innovation Factory — a medical device incubator, and Chairman and Managing Director of Accuitive Medical Ventures, a venture capital fund with over $230M of AUM.
Prior to his current position, Mr. Weldon was a cofounder, CEO and chairman of Novoste Corporation, where he grew the business from its inception through its IPO with a peak market cap of $1.2B.
Tom volunteers his time as an Advisory Board member for the Buck Institute for Research on Aging and the Purdue University Weldon School of Biomedical Engineering.
As co-founder of Accuitive Medical Ventures, Charlie brings nearly 40 years of operating experience, as well as expansive research and technical experience in the medical device industry. Charlie currently serves as a board member for CardioFocus. He is also a board observer at Intuity and AcuFocus. He currently is an Independent director at Femasys, a commercial stage company in the Feminine Healthcare space.
Charlie co-founded The Innovation Factory and serves as its Vice Chairman, co-founding numerous companies including: Cerebral Vascular Applications, Neuronetics, AcuFocus, , LipoSonix, NeoVista, Cellutions, Novalign, AqueSys, Halscion, and Sebacia.
Charlie was co-founder of Novoste Puerto Rico, along with Tom Weldon, where his efforts as a director and executive were critical to its ultimate success and sale to NAMIC, a division of Angiodynamics. He was subsequently a co-founder at Novoste Corporation, a vascular brachytherapy solution to restenosis, ultimately acquired by Best Medical.
Before forming Novoste, Charlie held positions with Cordis Corporation, Key Pharmaceuticals and Parke-Davis/Warner Lambert in executive, senior engineering and project management roles. Prior to several years in pharmaceutical design and manufacturing, he held various roles in the petrochemical and nuclear power industries.
Charlie received a B.S. in Mechanical Engineering from the New Jersey Institute of Technology. He attended Kenan Flagler at the University of North Carolina for Management Technology.
He holds over 30 issued U.S. and various International patents on medical devices and processes.
As CFO of Accuitive Medical Ventures, Gordy brings nearly 40 years of financial and operating experience, with seventeen years in the medical device industry. Gordy also serves as CFO of The Innovation Factory (TIF).
Gordy’s industry experience covers entrepreneurial and mature businesses ranging from pre-revenue start-up to $2.0 billion revenue market leader, spanning high technology, internet and E-commerce, EDI, life sciences, private equity, manufacturing, distribution, advertising, publishing, and consulting services. Extensive European exposure with premier global companies.
Developed financial organization and support system for TIF, TIF portfolio companies, and AMV’s venture capital fund with $230 million under management. Served as CFO for all TIF portfolio companies during founding and initial star-up stage, including: Cerebral Vascular Applications, LipoSonix, Neuronetics, AcuFocus, NeoVista, Cellutions, Novalign, AqueSys, Halscion, and Sebacia. Managed all finance and administration for AMV, and for TIF and TIF portfolio companies through their founding and early development stage.
Prior to joining TIF and AMV, Gordy was a proven senior leader at General Electric Company, Dun & Bradstreet Corporation, and WebMD Corporation, with experience in start-up, turnaround, and high growth business environments. His success in those companies reflects his strong financial and operational perspective and experience in business planning and day-to-day finance and business operations.
Throughout his career, he has been responsible for all financial and accounting operations including accounting, budgeting, management reporting, operational analysis, business unit support, and integration activities for acquired businesses. In various roles throughout his career, he has also had responsibilities for customer service, HR and IT activities.
Gordy received a B.S. with a double major in Accounting and Finance from Lehigh University. During his tenure at GE, he participated in many development programs, including GE’s Financial Management Program, Business Management and Advanced Marketing Management Programs, and Executive Development Program.
Cory is a Principal with Accuitive Medical Ventures and VP Clinical Marketing and Business Development for Sebacia (a TIF-founded company). Cory is currently a board observer for Myoscience.
Cory was the Program Manager for AqueSys from its inception through its transition out of TIF. Following the transition to permanent management, Cory remained involved with the company as a board observer until its exit to Allergan in 2015. For AqueSys, Cory managed the transformation of an academic invention into a product and through its initial clinical studies internationally. In his role with AqueSys, Cory met with FDA, grew the company’s patent portfolio, and eventually successfully transitioned the company to a management team focused on positioning AqueSys for FDA approval and commercial launch.
Cory has experience in conducting investor due diligence in multiple disease states across multiple technologies. He has successfully raised equity and debt financing for portfolio companies. Cory has been responsible for vetting new investment opportunities for AMV and building business plans for new TIF companies.
Operationally, Cory has experience in new product development of medical technologies, designing and conducting clinical studies worldwide, commercially launching products in Europe, developing regulatory strategies, and managing intellectual property portfolios.
Cory joined TIF from Novoste Corporation where he was a Product Manager focusing on new growth opportunities in addition to holding various positions of increasing responsibility within R&D.
Cory is an author of 2 published papers and 1 book chapter and is an inventor on 7 issued US patents and additional pending applications.
Cory holds a B.S. and M.S. in Biomedical Engineering from Tulane University and an M.B.A. from Emory University.
Anthony is Chief Executive Officer of The Innovation Factory (TIF) since 2005 and co-founder and CEO of Sebacia since 2010. Prior to TIF Anthony served as Chief Operating Officer of BTG plc, a UK public-listed specialty pharmaceutical company. Anthony has managed successful AMV investments in and served on the boards of AqueSys Inc. (co-founder, Board member since 2009, sold to Allergan; $725M Ophthalmology Device), Wave Tec Vision® ( Board Member, WaveTec Vision Inc. 2013-2014, sold to Alcon, Inc.; $350M Ophthalmology Device), Board Member, Myoscience Inc. 2013-Present Orthopaedic Device), and Halscion Inc (keloid scar treatment). At BTG plc. Anthony was responsible for BTG’s global business in the commercialization of Life Science (Ageing, Oncology and Neurosciences), IT and Engineering (Telecoms/Semiconductor) and Healthcare (Medical Device) technologies.
Anthony has experience in strategy development and operational management, a track record of achievement in developing and introducing technologies to physical and life science markets.
In 1997 Anthony helped established a technology venture company (Primaxis Technology Ventures) in partnership with the Royal Bank of Canada. As the BTG member of the Primaxis Board and Investment Committee he participated in deploying over $100M. Investments included Spotwave Wireless, Silicon Optix and Meriton Networks.
During Anthony’s tenure at BTG plc, he was responsible for expanding the market position for life science clinical development programs. Building a pipeline of over 10 compounds in lead identification, pre-clinical, IND or Phase I development activities. Anthony also lead the activities for medical device clearance EU approval and IDE.
Anthony's experience includes operations, product development, intellectual property management, financial management, and fundraising for both public and private companies, as well as development and creation of technology-based entities.
Prior positions include engineering and marketing roles with Philips Medical Systems and Stone & Webster Engineering.